The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas
Fig 1
Representative NRF2 immunostaining in endometrial tumors.
Immunohistochemical assay using NRF2 (clone A-10, SantaCruz) monoclonal antibody, revealed with Leica Bond Polymer Refine Detection System Kit. 10X objective. A: endometrioid grade I, copy number low-like tumor–stage IB. NRF2 high case. B: serous carcinoma copy-number low-like tumor, stage IIIC2 –NRF2 high case. C: carcinosarcoma, copy number high-like tumor–stage IB. NRF2 intermediate case. D. endometrioid grade I, copy number low-like tumor–stage IB. NRF2 negative/low case. Note that: A: sample with NRF2 activating mutations (KEAP1 p.R336*).